Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03092453 · ClinicalTrials.gov registry record · Phase 1
Dendritic Cell Vaccination in Patients With Advanced Melanoma
A Phase 1 study of Melanoma, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT03092453: Completed Phase 1 study of Melanoma, sponsored by University of Pennsylvania.
NCT03092453 is a Phase 1 study of Melanoma that has completed, run by University of Pennsylvania. The registered enrollment target is 5 participants, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03092453, a Phase 1 study of Melanoma, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells.
Primary Outcome
Immune response measuring increased numbers of peptide specific T cells as calculated by the tetramer assay. The numbers of Peptide Specific T Cells are reported as the percent of CD8+ T cells that were p/HLA multimer positive for each antigen.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- BIOLOGICAL Mature dendritic cell (DC) vaccine
- DRUG Cyclophosphamide 300mg/m^2
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2023-03-31 |
| Phase | Phase 1 |
What the finished NCT03092453 record still lists
NCT03092453 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 707-participant average among 266 other Melanoma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03092453 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03092453 about?
NCT03092453 is a clinical study titled "Dendritic Cell Vaccination in Patients With Advanced Melanoma". The purpose of this study is to investigate a method of using dendritic cells (a kind of white blood cell) as a vaccine to stimulate your own immune system to react to your melanoma cells.
What is the current status of trial NCT03092453?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-05-01. Estimated completion is 2023-03-31.
What conditions does trial NCT03092453 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT03092453?
The interventions under investigation include: Pembrolizumab (DRUG), Mature dendritic cell (DC) vaccine (BIOLOGICAL), Cyclophosphamide 300mg/m^2 (DRUG).
Who is sponsoring clinical trial NCT03092453?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03092453 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03092453's enrollment target sits among peer trials
5 264th of 266 higher than 3 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI